The estimated Net Worth of Rowena Albanna is at least $368 Thousand dollars as of 1 June 2021. Ms. Albanna owns over 3,400 units of ADiTx Therapeutics stock worth over $368,294 and over the last 4 years she sold ADTX stock worth over $0. In addition, she makes $0 as Chief Operating Officer at ADiTx Therapeutics.
Sign up
Ms. Albanna ADTX stock SEC Form 4 insiders trading
Rowena has made over 1 trades of the ADiTx Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently she bought 3,400 units of ADTX stock worth $9,962 on 1 June 2021.
The largest trade she's ever made was buying 3,400 units of ADiTx Therapeutics stock on 1 June 2021 worth over $9,962. On average, Rowena trades about 486 units every 0 days since 2020. As of 1 June 2021 she still owns at least 751,620 units of ADiTx Therapeutics stock.
You can see the complete history of Ms. Albanna stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Rowena Albanna biography
Rowena Albanna serves as Chief Operating Officer of the Company. From 2017 to immediately prior to her appointment as Chief Operating Officer, Ms. Albanna was an independent operations consultant for the Company. Prior thereto, from 2013 to 2017 Ms. Albanna was the Chief Operating Officer of ieCrowd, a Company that helps develop and commercialize innovations in the life, health and wellness fields. Ms. Albanna received a bachelor of science degree from California State University, San Bernardino in 1988.
How old is Rowena Albanna?
Rowena Albanna is 54, she's been the Chief Operating Officer of ADiTx Therapeutics since 2020. There are 5 older and 5 younger executives at ADiTx Therapeutics. The oldest executive at ADiTx Therapeutics, Inc. is Dr. Joachim-Friedrich Kapp M.D., Ph.D., 79, who is the Sr. VP of Clinical Devel. - Autoimmunity.
What's Rowena Albanna's mailing address?
Rowena's mailing address filed with the SEC is C/O ADITXT, INC., 737 N. FIFTH STREET, SUITE 200, RICHMOND, VA, 23219.
Insiders trading at ADiTx Therapeutics
Over the last 4 years, insiders at ADiTx Therapeutics have traded over $691,184 worth of ADiTx Therapeutics stock and bought 24,613 units worth $89,662 . The most active insiders traders include Paribas Securities Corp Bnp, Corinne Pankovcin, and Jeffrey W. Runge. On average, ADiTx Therapeutics executives and independent directors trade stock every 93 days with the average trade being worth of $2,473. The most recent stock trade was executed by Paribas Securities Corp Bnp on 6 September 2023, trading 20,800 units of ADTX stock currently worth $691,184.
What does ADiTx Therapeutics do?
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune reprogramming and monitoring. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
What does ADiTx Therapeutics's logo look like?
Complete history of Ms. Albanna stock trades at ADiTx Therapeutics
ADiTx Therapeutics executives and stock owners
ADiTx Therapeutics executives and other stock owners filed with the SEC include:
-
Amro Albanna,
Chairman of the Board, President, Chief Executive Officer -
Corinne D. Pankovcin CPA, CPA, M.B.A.,
Pres -
Amro A. Albanna,
Co-Founder, Chairman & CEO -
Dr. Shahrokh Shabahang D.D.S., M.S., Ph.D.,
Co-Founder, Chief Innovation Officer, Sec. & Director -
Shahrokh Shabahang,
Chief Innovation Officer, Director -
Jeffrey Runge,
Independent Director -
Namvar Kiaie,
Independent Director -
Brian Brady,
Independent Director -
Laura Anthony,
Independent Director -
Rowena Albanna,
Chief Operating Officer -
Corinne Pankovcin,
Chief Financial Officer -
Dr. Joachim-Friedrich Kapp M.D., Ph.D.,
Sr. VP of Clinical Devel. - Autoimmunity -
Dr. Dolly B. Tyan Ph.D.,
Sr. VP of Clinical Devel. Â Transplantation -
Jennifer Lee,
Director of HR -
Matthew M. Shatzkes,
Chief Legal Officer & Gen. Counsel -
Rowena Albanna,
Chief Operating Officer -
Thomas J. Farley CPA,
Chief Financial Officer -
Lauren Chung,
Director -
Charles Athle Nelson,
Director -
Thomas J Farley,
Chief Financial Officer -
Paribas Securities Corp Bnp,